<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335647</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000486281</org_study_id>
    <secondary_id>IMMUNECON-FM-CL1</secondary_id>
    <secondary_id>UPCC-IRB-5</secondary_id>
    <secondary_id>UPCC-09405</secondary_id>
    <secondary_id>UPCC-803972</secondary_id>
    <nct_id>NCT00335647</nct_id>
  </id_info>
  <brief_title>Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma</brief_title>
  <official_title>A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in Patients With Advanced Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune Control</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop&#xD;
      the growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine and&#xD;
      to see how well it works in treating patients with refractory advanced multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of high-dose fluphenazine hydrochloride in patients with refractory&#xD;
           advanced multiple myeloma.&#xD;
&#xD;
        -  Determine the pharmacological properties of this drug.&#xD;
&#xD;
        -  Determine the effectiveness of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive high-dose fluphenazine hydrochloride IV 3 times on day 1. Treatment repeats&#xD;
      every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of patients receive escalating doses of fluphenazine hydrochloride until the maximum&#xD;
      tolerated dose is determined.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluphenazine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed multiple myeloma&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
               -  Must be refractory to ≥ 2 different methods of standard treatment&#xD;
&#xD;
          -  Measurable disease, defined as serum paraprotein ≥ 1g/L or urine light chain ≥ 200&#xD;
             mg/24 hours&#xD;
&#xD;
          -  No brain involvement or leptomeningeal disease&#xD;
&#xD;
          -  No spinal cord compression unless the following criteria are met:&#xD;
&#xD;
               -  Patient has undergone prior surgery or radiotherapy&#xD;
&#xD;
               -  Neurological findings are ≤ grade 1&#xD;
&#xD;
               -  Patient is off steroids for spinal cord edema or is on a stable regimen of ≤ 10&#xD;
                  mg/day of prednisone or equivalent&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 (ECOG PS 3 allowed if related to skeletal lesions)&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL* (no transfusion within the past 7 days)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  LVEF ≥ 40%&#xD;
&#xD;
          -  QTc &lt; 450 msec&#xD;
&#xD;
          -  No evidence of dysrhythmias on EKG&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension, defined as systolic blood pressure (BP) &gt; 180 mm Hg&#xD;
             and/or diastolic BP &gt; 105 mm Hg&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No HIV, hepatitis B, or hepatitis C infection&#xD;
&#xD;
          -  No history of psychosis&#xD;
&#xD;
          -  No history of subcortical brain damage&#xD;
&#xD;
          -  No hypersensitivity to fluphenazine hydrochloride or other phenothiazines&#xD;
&#xD;
          -  No history of seizures or extrapyramidal symptoms&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix NOTE: *Patients with values outside of this&#xD;
             range due to infiltration by myeloma may be allowed at the discretion of the&#xD;
             investigator&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 21 days since prior chemotherapy, immunotherapy, or radiotherapy&#xD;
&#xD;
          -  At least 21 days since prior and no concurrent systemic steroids&#xD;
&#xD;
               -  Patients who have been taking chronically administered steroids for ≥ 1 month at&#xD;
                  a dose ≤ 10 mg/day of prednisone or equivalent are eligible&#xD;
&#xD;
          -  At least 28 days since prior investigational agents&#xD;
&#xD;
          -  At least 6 weeks since prior selective serotonin reuptake inhibitors (SSRIs) (a&#xD;
             wash-out period equivalent to 5 times the terminal elimination half-life is required&#xD;
             for tricyclic antidepressants or norepinephrine reuptake inhibitors)&#xD;
&#xD;
          -  No concurrent SSRIs, tricyclic antidepressants, or norepinephrine reuptake inhibitors&#xD;
&#xD;
          -  No concurrent dialysis therapy&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors except epoetin alfa&#xD;
&#xD;
               -  Treatment with hematopoietic growth factors may be started during study if&#xD;
                  patient develops or has progressive cytopenia&#xD;
&#xD;
          -  No concurrent anticholinergics or other antipsychotics&#xD;
&#xD;
          -  No concurrent antiseizure drugs except Neurontin for treatment of neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluphenazine</mesh_term>
    <mesh_term>Fluphenazine depot</mesh_term>
    <mesh_term>Fluphenazine enanthate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

